Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lanifibranor trial in adults with non-cirrhotic NASH and liver fibrosis
MOH_2021-11-02_010365Phase 3Recruiting
- Sponsor
- Inventiva
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (3 arms), sponsored by Inventiva. Started Aug 2021; status: recruiting.
02
Drugs
lanifibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on MOH_2021-11-02_010365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-02_010365.